Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common cancer, but is the second leading cause of cancer deaths, partially due to its heterogeneity and drug resistance. Sorafenib is the only medical treatment with a proven efficacy against advanced HCC, but its overall clinical efficacy is still mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Min, Xu, Huijuan, Liao, Xin-Hua, Peng Chen, Champ, Li Zhang, Arina, Lu, Wenxian, Wang, Long, Yang, Dayun, Wang, Jichuang, Liu, Hekun, Zhen Zhou, Xiao, Ping Lu, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444702/
https://www.ncbi.nlm.nih.gov/pubmed/28404959
http://dx.doi.org/10.18632/oncotarget.15967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444702/
https://www.ncbi.nlm.nih.gov/pubmed/28404959
http://dx.doi.org/10.18632/oncotarget.15967

Ejemplares similares